Tumor shrinkage was also seen in a patient with adrenal carcinoma with FGFR3-TACC3/FGFR2- CCDC6 (FGFR3-TACC3 being the predominant translocation), who received treatment for 10 months before disease progression. Here, FGFR3 is linked to neoplasm.